LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 3 of total 3

Search options

  1. Article: Real-world effectiveness of elexacaftor/tezacaftor/ivacaftor on the burden of illness in adolescents and adults with cystic fibrosis.

    Keens, Thomas / Hoffman, Veena / Topuria, Ia / Elder, Ken / Cerf, Shannon / Mulder, Kyra / Roberts, Jon / Lysinger, Jerimiah / Del Carmen Reyes, Maria / Berdella, Maria / Cairns, Anne Marie / Jain, Manu / Ganapathy, Vaidyanathan / Lou, Yiyue / Morcos, Bassem / Wu, Chuntao / Sass, Laura

    Heliyon

    2024  Volume 10, Issue 7, Page(s) e28508

    Abstract: Background: Elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) has been shown to be safe and efficacious in people with cystic fibrosis (CF) aged ≥2 years. Here, we describe results from an observational study assessing change in burden of illness following ...

    Abstract Background: Elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) has been shown to be safe and efficacious in people with cystic fibrosis (CF) aged ≥2 years. Here, we describe results from an observational study assessing change in burden of illness following initiating ELX/TEZ/IVA in real-world settings.
    Methods: This US-based, multicenter, observational study used data from electronic medical records to evaluate real-world burden of illness before and after ELX/TEZ/IVA initiation in people with CF aged ≥12 years heterozygous for
    Results: Overall, 206 people with CF were enrolled (mean [SD] age 22.5 [11.1] years; 192 [93.2%] with
    Conclusions: ELX/TEZ/IVA treatment was associated with improved lung function, increased BMI, reduced frequency of PEx, and improved (i.e., reduced) HbA1c. These results confirm the broad clinical benefits of ELX/TEZ/IVA seen in clinical trials and show the potential for ELX/TEZ/IVA to improve markers of glucose metabolism.
    Language English
    Publishing date 2024-03-26
    Publishing country England
    Document type Journal Article
    ZDB-ID 2835763-2
    ISSN 2405-8440
    ISSN 2405-8440
    DOI 10.1016/j.heliyon.2024.e28508
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Airway inflammation accelerates pulmonary exacerbations in cystic fibrosis.

    Liou, Theodore G / Argel, Natalia / Asfour, Fadi / Brown, Perry S / Chatfield, Barbara A / Cox, David R / Daines, Cori L / Durham, Dixie / Francis, Jessica A / Glover, Barbara / Helms, My / Heynekamp, Theresa / Hoidal, John R / Jensen, Judy L / Kartsonaki, Christiana / Keogh, Ruth / Kopecky, Carol M / Lechtzin, Noah / Li, Yanping /
    Lysinger, Jerimiah / Molina, Osmara / Nakamura, Craig / Packer, Kristyn A / Paine, Robert / Poch, Katie R / Quittner, Alexandra L / Radford, Peggy / Redway, Abby J / Sagel, Scott D / Szczesniak, Rhonda D / Sprandel, Shawna / Taylor-Cousar, Jennifer L / Vroom, Jane B / Yoshikawa, Ryan / Clancy, John P / Elborn, J Stuart / Olivier, Kenneth N / Adler, Frederick R

    iScience

    2024  Volume 27, Issue 3, Page(s) 108835

    Abstract: Airway inflammation underlies cystic fibrosis (CF) pulmonary exacerbations. In a prospective multicenter study of randomly selected, clinically stable adolescents and adults, we assessed relationships between 24 inflammation-associated molecules and the ... ...

    Abstract Airway inflammation underlies cystic fibrosis (CF) pulmonary exacerbations. In a prospective multicenter study of randomly selected, clinically stable adolescents and adults, we assessed relationships between 24 inflammation-associated molecules and the future occurrence of CF pulmonary exacerbation using proportional hazards models. We explored relationships for potential confounding or mediation by clinical factors and assessed sensitivities to treatments including CF transmembrane regulator (CFTR) protein synthesis modulators. Results from 114 participants, including seven on ivacaftor or lumacaftor-ivacaftor, representative of the US CF population during the study period, identified 10 biomarkers associated with future exacerbations mediated by percent predicted forced expiratory volume in 1 s. The findings were not sensitive to anti-inflammatory, antibiotic, and CFTR modulator treatments. The analyses suggest that combination treatments addressing RAGE-axis inflammation, protease-mediated injury, and oxidative stress might prevent pulmonary exacerbations. Our work may apply to other airway inflammatory diseases such as bronchiectasis and the acute respiratory distress syndrome.
    Language English
    Publishing date 2024-01-09
    Publishing country United States
    Document type Journal Article
    ISSN 2589-0042
    ISSN (online) 2589-0042
    DOI 10.1016/j.isci.2024.108835
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  3. Article ; Online: Prospective multicenter randomized patient recruitment and sample collection to enable future measurements of sputum biomarkers of inflammation in an observational study of cystic fibrosis.

    Liou, Theodore G / Adler, Frederick R / Argel, Natalia / Asfour, Fadi / Brown, Perry S / Chatfield, Barbara A / Daines, Cori L / Durham, Dixie / Francis, Jessica A / Glover, Barbara / Heynekamp, Theresa / Hoidal, John R / Jensen, Judy L / Keogh, Ruth / Kopecky, Carol M / Lechtzin, Noah / Li, Yanping / Lysinger, Jerimiah / Molina, Osmara /
    Nakamura, Craig / Packer, Kristyn A / Poch, Katie R / Quittner, Alexandra L / Radford, Peggy / Redway, Abby J / Sagel, Scott D / Sprandel, Shawna / Taylor-Cousar, Jennifer L / Vroom, Jane B / Yoshikawa, Ryan / Clancy, John P / Elborn, J Stuart / Olivier, Kenneth N / Cox, David R

    BMC medical research methodology

    2019  Volume 19, Issue 1, Page(s) 88

    Abstract: Background: Biomarkers of inflammation predictive of cystic fibrosis (CF) disease outcomes would increase the power of clinical trials and contribute to better personalization of clinical assessments. A representative patient cohort would improve ... ...

    Abstract Background: Biomarkers of inflammation predictive of cystic fibrosis (CF) disease outcomes would increase the power of clinical trials and contribute to better personalization of clinical assessments. A representative patient cohort would improve searching for believable, generalizable, reproducible and accurate biomarkers.
    Methods: We recruited patients from Mountain West CF Consortium (MWCFC) care centers for prospective observational study of sputum biomarkers of inflammation. After informed consent, centers enrolled randomly selected patients with CF who were clinically stable sputum producers, 12 years of age and older, without previous organ transplantation.
    Results: From December 8, 2014 through January 16, 2016, we enrolled 114 patients (53 male) with CF with continuing data collection. Baseline characteristics included mean age 27 years (SD = 12), 80% predicted forced expiratory volume in 1 s (SD = 23%), 1.0 prior year pulmonary exacerbations (SD = 1.2), home elevation 328 m (SD = 112) above sea level. Compared with other patients in the US CF Foundation Patient Registry (CFFPR) in 2014, MWCFC patients had similar distribution of sex, age, lung function, weight and rates of exacerbations, diabetes, pancreatic insufficiency, CF-related arthropathy and airway infections including methicillin-sensitive or -resistant Staphylococcus aureus, Pseudomonas aeruginosa, Burkholderia cepacia complex, fungal and non-tuberculous Mycobacteria infections. They received CF-specific treatments at similar frequencies.
    Conclusions: Randomly-selected, sputum-producing patients within the MWCFC represent sputum-producing patients in the CFFPR. They have similar characteristics, lung function and frequencies of pulmonary exacerbations, microbial infections and use of CF-specific treatments. These findings will plausibly make future interpretations of quantitative measurements of inflammatory biomarkers generalizable to sputum-producing patients in the CFFPR.
    MeSH term(s) Adolescent ; Adult ; Cystic Fibrosis/microbiology ; Cystic Fibrosis/pathology ; Cystic Fibrosis/therapy ; Female ; Humans ; Lung/microbiology ; Lung/pathology ; Lung/physiopathology ; Male ; Methicillin-Resistant Staphylococcus aureus/isolation & purification ; Methicillin-Resistant Staphylococcus aureus/physiology ; Middle Aged ; Patient Selection ; Prospective Studies ; Sputum/microbiology ; Staphylococcal Infections/microbiology ; Staphylococcal Infections/pathology ; Staphylococcal Infections/therapy ; Young Adult
    Language English
    Publishing date 2019-04-26
    Publishing country England
    Document type Journal Article ; Multicenter Study ; Observational Study ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 2041362-2
    ISSN 1471-2288 ; 1471-2288
    ISSN (online) 1471-2288
    ISSN 1471-2288
    DOI 10.1186/s12874-019-0705-0
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top